April 26, 2018 10:18 AM EDT

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

Amber Tong

→ Antibacterial R&D accelerator CARB-X has granted Achaogen $AKAO an award worth up to $12 million to fuel its early-stage programs in for multi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M

Amber Tong

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Achao­gen earns $12M award for next-gen an­tibi­otics; En­do ac­quires Som­er­set for $190M

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M